Calidi Biotherapeutics Refiles Consolidated Financial Statements After Reverse Stock Split

Calidi Biotherapeutics, Inc. has recently filed a Form 8-K with the U.S. Securities and Exchange Commission to refile its Consolidated Financial Statements for the Fiscal Year ended December 31, 2023. The company indicated that the refile is to reflect the retroactive effect of its 1-for-10 reverse stock split of the shares of its Common Stock, par value $0.0001 per share, effective on July 15, 2024.

The auditor report and the consolidated financial statements, which include the impact of the Reverse Stock Split, have been attached as exhibits to the filing. The Form 8-K emphasizes that this refiling is solely for the mentioned purposes, with all other information in the 2023 Annual Report remaining unchanged. Notably, the Exhibits included in the Current Report do not encompass events occurring after the filing of the 2023 Annual Report and should be viewed in conjunction with information in the original annual report.

Furthermore, in the attached Exhibit 99.1, publicized within the filing, Nordstrom, Inc. (NYSE: JWN) reported a notable increase in total Company net sales and comparable sales for the nine-week holiday period ended January 4, 2025, compared to the corresponding period in 2023. Erik Nordstrom, the CEO of Nordstrom, Inc., acknowledged the strength of the Company’s offering and the surpassing of holiday sales expectations.

Following the holiday results, Nordstrom updated its fiscal 2024 outlook, anticipating revenue growth of 1.5 to 2.5 percent and comparable sales growth of 2.5 to 3.5 percent against the previous fiscal year. The Company is scheduled to release its fourth-quarter and full-year 2024 financial results after the close of the financial markets on March 4, 2025.

Investors and stakeholders are advised to review the detailed financial performance information to be provided by Nordstrom during the forthcoming financial results report.

In acknowledging both the refile of Calidi Biotherapeutics’ financial statements and the financial performance update from Nordstrom, Inc., market participants are advised to stay informed about developments within the respective companies and their implications in the market.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Calidi Biotherapeutics’s 8K filing here.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.